• 1\) Healthy volunteers who fully understand the content, process, and possible adverse event of the study and capable of giving written informed consent form.

• 2\) Male or female between 18 and 55 years of age (inclusive), at the time of signing the informed consent form.

• 3\) Body mass index (BMI) range within 18\

⁃ 30 kg/m2 (inclusive), and body weight of ≥ 50.0 kg for male and ≥ 45.0 kg for female.

• 4\) Healthy volunteers who must be confirmed as negative in the SARS-CoV-2 test on Day -2 (admission).

• 5\) Healthy volunteers with no significant medical history judged by the Investigator and in good health, fully physical examinations, vital signs, 12-lead electrocardiograms (12-ECGs), clinical laboratory tests (hematology, urinalysis, blood chemistry and coagulation test), serum virology test.

• 6\) Females must be non- pregnant, non- lactating and must have negative serum pregnancy test at screening. Women of child bearing potential and males must be willing to use highly effective acceptable forms of contraception from screening to 6 months after the last study drug administration. Males and females must be willing to avoid donating sperm or egg respectively during the study period and 6 months after the last dose of IP.

• 7\) All HVs who must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.